ProNAi Therapeutics, which is developing cancer therapies based on DNA interference, raised $138 million by offering 8.1 million shares at $17. ProNAi Therapeutics plans to list on the NASDAQ under the symbol DNAI. ProNAi Therapeutics initially filed confidentially on 4/8/2015. Jefferies and BofA Merrill Lynch acted as lead managers on the deal.
